Serum Calcification Propensity Is a Strong and Independent Determinant of Cardiac and All-Cause Mortality in Kidney Transplant Recipients

• DOI: 10.1111/ajt.13443
• Publication Date: 2015-09-16T20:28:35Z
• Authors: D.O. Dahle; A. Åsberg; A. Hartmann; H. Holdaas; M. Bachtler; T.G. Jenssen; M. Dionisi; A. Pasch
• Keywords: Adult; Graft Rejection; Male; Graft Survival; Calcinosis; Middle Aged; Pulse Wave Analysis; Kidney Function Tests; Prognosis; Kidney Transplantation; 3. Good health; 03 medical and health sciences; Calcification, Physiologic; Postoperative Complications; 0302 clinical medicine; Cardiovascular Diseases; Risk Factors; Humans; Kidney Failure, Chronic; Female; Aged; Follow-Up Studies; Glomerular Filtration Rate

Calcification of the vasculature is associated with cardiovascular disease and death in kidney transplant recipients. A novel functional blood test measures calcification propensity by quantifying the transformation time (T50 ) from primary to secondary calciprotein particles. Accelerated T50 indicates a diminished ability of serum to resist calcification. We measured T50 in 1435 patients 10 weeks after kidney transplantation during 2000-2003 (first era) and 2009-2012 (second era). Aortic pulse wave velocity (APWV) was measured at week 10 and after 1 year in 589 patients from the second era. Accelerated T50 was associated with diabetes, deceased donor, first transplant, rejection, stronger immunosuppression, first era, higher serum phosphate and lower albumin. T50 was not associated with progression of APWV. During a median follow-up of 5.1 years, 283 patients died, 70 from myocardial infarction, cardiac failure or sudden death. In Cox regression models, accelerated T50 was strongly and independently associated with both all-cause and cardiac mortality, low versus high T50 quartile: hazard ratio 1.60 (95% confidence interval [CI] 1.00-2.57), ptrend = 0.03, and 3.60 (95% CI 1.10-11.83), ptrend = 0.02, respectively. In conclusion, calcification propensity (T50 ) was strongly associated with all-cause and cardiac mortality of kidney transplant recipients, potentially via a cardiac nonAPWV-related pathway. Whether therapeutic improvement of T50 improves outcome awaits clarification in a randomized trial.